<figure><img src="image_1.png" /></figure>

HAL
open science

# Iron and energy metabolic interactions in Treg-mediated immune regulation

Frédérique Savagner, Thomas Farge, Zoubida Karim, Meryem Aloulou

► To cite this version:

Frédérique Savagner, Thomas Farge, Zoubida Karim, Meryem Aloulou. Iron and energy metabolic interactions in Treg-mediated immune regulation. Frontiers in Immunology, 2025, 16, pp.1554028. 10.3389/fimmu.2025.1554028. hal-05378486

HAL Id: hal-05378486

https://hal.science/hal-05378486v1

Submitted on 23 Nov 2025

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_2.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
<figure><img src="image_3.png" /></figure>

Check for updates

OPEN ACCESS

EDITED BY
Yasuhiro Shimojima,
Shinshu University, Japan

REVIEWED BY
Silvia Piconese,
Sapienza University of Rome, Italy

*CORRESPONDENCE

Frédérique Savagner

frederique.savagner@inserm.fr

Meryem Aloulou

meryem.aloulou@inserm.fr

RECEIVED 02 January 2025

ACCEPTED 03 March 2025

PUBLISHED 19 March 2025

CITATION

Savagner F, Farge T, Karim Z and Aloulou M (2025) Iron and energy metabolic interactions in Treg-mediated immune regulation.
*Front. Immunol.* 16:1554028.
doi: 10.3389/fimmu.2025.1554028

COPYRIGHT

© 2025 Savagner, Farge, Karim and Aloulou.
This is an open-access article distributed under the terms of the [Creative Commons Attribution License (CC BY)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Iron and energy metabolic interactions in Treg-mediated immune regulation

Frédérique Savagner<fnref n="1" />,²,³*, Thomas Farge<fnref n="1" />,², Zoubida Karim<fnref n="4" /> and Meryem Aloulou<fnref n="4" />*

Immunometabolism, the study of how metabolic processes influence immune cell function, has emerged as a critical field in understanding the regulation of immune tolerance and the pathological mechanisms underlying autoimmune diseases. Intracellular metabolic pathways not only provide the necessary energy for immune cell survival and activity but also shape the differentiation, phenotype, proliferation, and effector functions of immune cells. This is particularly evident in CD4+ Foxp3+ regulatory T cells (Treg), which are pivotal for maintaining immune homeostasis and preventing autoimmune reactions. Strong experimental evidence highlights the profound impact of metabolism on Treg. Their anti-inflammatory function and ability to suppress excessive immune responses depend on the integration of metabolic cues with their transcriptional and signaling networks. Iron metabolism and mitochondrial dynamics are among the key factors influencing Treg function. This review focuses on how iron and mitochondrial metabolism shape Treg biology and function.

KEYWORDS

Foxp3, Treg, mitochondria, iron, ROS, immunoregulation

Introduction

Among the various T cell lineages with suppressive or regulatory functions, the CD4+Foxp3+ regulatory T cell (Treg) subset has been the primary focus of research. Treg are essential for maintaining tolerance and immune homeostasis, with altered Treg function leading to autoimmune disease and immunopathology.

This pivotal role is underscored by the association of FOXP3 loss of function mutations with severe lymphoproliferative autoimmune disorders, such as IPEX syndrome in humans (1) and the scurfy phenotype in mice (2). These findings, combined with the identification of Foxp3 as the master regulator of the CD4+CD25+ suppressive population (3–6), have established a consistent Treg phenotype and provided essential tools for investigating this

<footnote n="1">¹Biochemistry Laboratory, University of Toulouse, Toulouse, France, ²Inserm U1297, Institute of Metabolic and Cardiovascular Diseases (I2MC), Toulouse, France, ³Biochemistry Laboratory, Genetic and Hormonal Department, Federative Institute of Biology, Academic Hospital, Toulouse, France,</footnote>

<footnote n="4">⁴INFINITY, Toulouse Institute for Infectious and Inflammatory Diseases, INSERM U1291, CNRS U5051, University of Toulouse, Toulouse, France</footnote>
critical T cell subset. Recent studies have uncovered Foxp3-
independent mechanisms contributing to Treg dysfunction, further
emphasizing the complexity of their regulatory pathways (7, 8). This
highlights the need to explore how various factors, particularly
immunometabolism, influence Treg function. In this context, the
roles of iron metabolism and mitochondrial dynamics have gained
significant attention as key modulators of Treg activity.

This review focuses on how immunometabolism, with a
particular emphasis on iron and mitochondrial metabolism,
affects Treg function in the contexts of autoimmune diseases,
hypertension-associated conditions and instead of an aging.
Understanding these interactions will provide deeper insights into
Treg biology and their therapeutic potential in disease management.

Treg biology and function

Most Treg cells develop in the thymus and are classified as
thymus-derived Treg (tTreg) cells (9) characterized by a T cell
receptor (TCR) with relatively high affinity for self-antigen (10).
Additionally, Treg cells can differentiate from conventional T cells
in the periphery, forming peripherally-derived Treg cells (pTreg), or
be induced *in vitro* through stimulation with IL-2 and TGF-β,
known as induced Treg cells (iTreg) (11, 12), that are more prone to
be specific for foreign antigen. The tTreg are widely regarded as
more stable than pTreg (13). This stability issues from the thymic
environment, which provides a protected setting with minimal
external interference during their development and maturation.
This allows sufficient time for complete epigenetic remodeling,
resulting in stable and sustained Foxp3 expression.

By contrast, pTreg have a yet incomplete Treg-like epigenetic
imprint, making these cells more susceptible to loss of Foxp3
expression in the presence of strong inflammation. The stability of
the Treg lineage depends on continuous FOXP3 transcription, which
is maintained through changes in the methylation status of histones
and CpG-rich regions. This process results in a Treg-specific
hypomethylation pattern, known as the major Treg-specific
demethylated region (TSDR), located within the second intron
enhancer of the FOXP3 gene, commonly referred to as conserved
non-coding sequence 2 (CNS2) (14). Epigenetic modifications, such
as DNA methylation and demethylation, play a crucial role in
maintaining Treg stability and function. DNA demethylation can
occur passively during DNA replication or actively through the
catalytic activity of the ten-eleven translocation (TET) family of
dioxygenases. These enzymes oxidize 5-methylcytosine (5mC) to 5-
hydroxymethylcytosine (5hmC) and other intermediates, ultimately
leading to the restoration of unmethylated cytosine at specific
genomic positions (15, 16).

The demethylation mechanism is modulated by iron and key
metabolites of the tricarboxylic acid cycle (TCA) that proved the
profound interplay between metabolism-associated environmental
signals, epigenetic modifications and Treg biology and function (17).
To adapt to both intrinsic and extrinsic cues, Tregs activate a nutrient-
sensing mechanism, orchestrating metabolic reprogramming to
maintain and enhance their activity. Recent advances in

immunometabolism have highlighted the critical role of
mitochondrial dynamics and iron homeostasis in regulating and
shaping Treg functionality (Figure 1 for illustrating interplay).

Iron metabolism in Treg

Trace element iron plays a vital role in T cell biology, serving as
an essential cofactor for numerous cellular and metabolic processes.
Ferroportin (FPN) and divalent metal transporter 1 (DMT1) are
central to iron uptake and transfer in the duodenum, regulated
adaptively by hepcidin to maintain iron homeostasis (18, 19). Since
DMT1 and FPN gene expression levels are highly dependent on
HIF-2α, this transcription factor has been considered as a key local
regulator of iron absorption, directly transactivating iron
transporter genes (20).

Upon activation, T cells markedly upregulate transferrin
receptor (TfR, CD71), a key protein that facilitates the uptake of
transferrin-bound iron from the serum (21). This imported iron is
indispensable for supporting T cell activation, proliferation, and
differentiation (22, 23). Thus, iron could modulate T cell function
through multiple mechanisms, including IL-2 secretion and
endosomal recycling. In a model of systemic lupus erythematosus
(SLE), these mechanisms may lead to iron accumulation in T cells
despite SLE patients' predisposition to low serum iron levels (23).
Elevated intracellular iron, in turn, alters mitochondrial respiration
and mitochondrial reactive oxygen species (ROS) production.

A recent study has shown that both human and mouse Treg
cells express iron-regulatory genes, including ferritin heavy chain
(FTH) (24). Since FTH regulates the intracellular pool of redox-
active Fe2+, it may influence TET enzymatic activity either directly -
by sequestering catalytic Fe2+ - or indirectly by modulating redox
homeostasis. A functional link between FTH ferroxidase activity
and TET function connects FTH to FOXP3 transcription and
expression, thereby impacting Treg function (25).

In addition to its role in post-transcriptional regulation, iron
binds to enzymes involved in gene expression, such as TET
dioxygenases, and directly interacts with certain transcription
factors (26). FTH may also regulate additional local iron-
dependent pathways that support Treg function, contributing to a
spatial mechanism of tolerance in intestinal tissue (27–29). Thus,
FTH is able to enhance HIF-2 expression, which induces c-Maf
expression in Treg cells - a key factor in maintaining immunological
tolerance to the microbiota. Notably, pentanoate, a microbiota-
derived metabolite, may promote intestinal Treg homeostasis by
modulating intracellular iron levels. Thus, in the intestine, perinatal
Treg expansion is jointly linked to iron homeostasis and bacterial
colonization. In a conditional CD71 knockout model, mice develop
a scurfy-like disease with a complete absence of Foxp3, along with
reduced bacterial proliferation due to limited iron availability (30).

The reliance of TET enzymes activity on iron availability
suggests that Treg lineage stability is closely linked to cellular iron
homeostasis, potentially involving a spatial mechanism of tolerance
in hypermetabolic regions (31).
<figure><img src="image_4.png" /><figcaption>FIGURE 1</figcaption></figure>

Iron and energy metabolism in Treg. Upon TCR engagement, glucose uptake by Tregs supports GSH synthesis, fuels the TCA cycle, and drives energy production through oxidative phosphorylation (OxPhos). The mammalian target of rapamycin (mTOR) pathway mediates a metabolic reprogramming of glucose metabolism towards lipid metabolism, enhancing the immunosuppressive functions of effector Tregs by facilitating metabolic and epigenetic modifications associated with iron homeostasis. TET, Ten Eleven Translocation enzyme; HDM, histone demethylase; GSH, glutathione; 3PG, 3-phosphoglycerate; ROS, Reactive Oxygen.

## Mitochondrial metabolism in Treg

Iron metabolism and iron-regulatory genes are intricately linked to TCA and oxidative phosphorylation (OxPhos) metabolism. Iron sulfur clusters act in the catalytic centers of number of important enzymes as cytochrome oxidase, citrate synthase, aconitase and succinate deshydrogenase. Moreover, intracellular ferrous iron is a critical component of redox centers of the respiratory chain complexes driving reactive oxygen species production. Signals through TCR and IL-2 provide inputs for mammalian target of rapamycin (mTOR) activation which in turn programs the suppressive function of Treg cells and induce a metabolic shift. mTORC1 does not directly affect the expression of Foxp3 but maintain Treg functions mainly by inhibition of the mTORC2 pathway (32). Using mTOR antagonist as Rapamycin, Treg function and fatty acid oxidation were enhanced promoting both tTreg and pTreg generation through AMPK pathway (33). The reprogramming of glucose metabolism mediated by the raptor/mTORC1 pathway to lipid metabolism and OxPhos mediates the enhancement of immunosuppressive functions in effector Treg. Notably, complex III of the respiratory chain, which include the Rieske iron-sulfur subunit, is the primary site for ROS generation in

both matrix mitochondria and cytosol. While ROS generation is essential for cellular signaling, decrease in ATP production and Gpx expression associated to excessive ROS can trigger ferroptosis, a regulated form of cell death implicated in various diseases (19). In Treg, lipid peroxidation and ferroptosis could be prevented by inducing the glutathione peroxidase Gpx4 that in turn is able to control CD71 expression and mitochondrial homeostasis (34). Thus, Gpx4 could protect activated-Treg by restoring cellular redox homeostasis.

A recent study has highlighted the metabolic-epigenetic role of respiratory chain complex III (35). Loss of complex III has been shown to result in global DNA hypermethylation without affecting the methylation status of canonical Treg genes. This effect is likely due to the accumulation of TCA metabolites such as succinate or fumarate, which inhibit TET-DNA demethylase activity by competing with the α-ketoglutarate cofactor. This inhibition disrupts Treg suppressive capacity, even without impairing their proliferation or survival. Therefore, Treg cell play a crucial role in maintaining peripheral T cell tolerance.

We are going to challenge the close relationship between iron homeostasis and energy metabolism in frequent chronic diseases and aging, in the context of Treg dysfunction.
Autoimmune diseases

In healthy individuals, Treg exhibit enhanced mitochondrial
metabolism, with the mitochondrial respiratory chain playing a
pivotal role in maintaining their suppressive capacity, stability, and
survival (36, 37). Conversely, in autoimmune diseases such as
multiple sclerosis (MS), inflammatory bowel disease, systemic
lupus erythematosus and rheumatoid arthritis (RA), Treg exhibit
a significant metabolic reprogramming signature, marked by
distinct features of mitochondrial dysfunction and oxidative
stress-induced cell death (38). Similarly, in the experimental
autoimmune encephalitis (EAE) mouse model, an MS-mouse
model, Treg show increased mitochondrial oxidative stress and
lysosomal dysfunction, triggering a cell death program (38). These
findings suggest that mitochondrial-regulated Treg may play a key
role in the onset and progression of autoimmune diseases affecting
the central nervous system.

Recent advances in understanding the pathogenesis of RA
highlight the intricate interplay among immune tolerance, cellular
metabolism, and aging. The loss of self-tolerance, which begins
decades before joint inflammation manifests, originates outside the
joint. RA patients display features of premature immune aging,
including mitochondrial stress, reduced ATP production, and
inflammasome activation, ultimately resulting in T cell
dysfunction and pyroptotic cell death (39–42). A key effector
molecule in RA pathogenesis is tumor necrosis factor (TNF),
which is abundantly produced in rheumatoid tissue lesions and is
a well-established therapeutic target. In RA T cells, metabolic
remodeling enables short-lived effector functions but
compromises energy production and mitochondrial fitness,
further amplifying TNF production (43). These insights place
cellular metabolism and mitochondrial dynamics at the heart of
RA pathogenesis, reshaping disease paradigms.

In SLE, iron metabolism plays a critical factor influencing
disease progression. Excessive iron accumulation, particularly in
the kidneys, plays a well-established role in exacerbating lupus
nephritis (LN), a severe manifestation of SLE. This iron deposition
leads to increased oxidative stress, contributing to heightened
disease activity. Beyond its direct effects on the kidneys, iron may
also impact immune regulation by influencing the function of Treg,
which are crucial for maintaining immune tolerance. Inflammatory
Treg in autoimmune diseases often exhibit heightened glycolytic
metabolism, leading to impaired suppressive function (44). This
dysfunction is further aggravated by iron overload, which
exacerbates oxidative stress and diminishes Treg capacity (45, 46).

Promisingly, interventions targeting iron accumulation, such as
iron chelators and hepcidin modulation, have shown significant
improvements in LN outcomes in animal models (47). Additionally,
dietary and metabolic approaches that reduce iron availability, such
as low-iron diets, promote Treg expansion and survival by limiting
the formation of ROS (48). By enhancing Treg function, iron
chelation not only mitigates renal damage but may also help
restore immune balance, thereby addressing a key mechanism of
disease progression.

These findings underscore the potential of targeting metabolic
pathways as a multifaceted therapeutic strategy for SLE (49). By
reducing oxidative damage and enhancing Treg function,
interventions aimed at regulating iron metabolism could provide
innovative approaches to manage lupus nephritis and the broader
systemic manifestations of SLE. Such strategies also illustrate the
broader relevance of metabolic interventions in addressing the
immunopathology of autoimmune diseases.

Treg metabolism in hypertension and
cardiovascular disease

Hypertension and cardiovascular diseases are profoundly
influenced by the intricate interplay of immune regulation, ROS
production, and metabolic reprogramming (50). Hypertension
pathogenesis is influenced by multiple molecular and cellular
factors, including ROS, which play a central role in the cellular
processes that drive blood pressure elevation and vascular
dysfunction (51). A key player in hypertension development is the
renin-angiotensin system (RAS), which stimulates pathological
cardiovascular remodeling (52). Overactivation of RAS contributes
to endothelial dysfunction, cardiac hypertrophy, heart failure, and
hypertension. The well-established link between high sodium intake
and an increased risk of hypertension and cardiovascular disease
further implicates immune cell metabolism in disease progression.
High salt exposure affects Treg immunometabolism, impairing their
suppressive function by reprogramming them into a pro-
inflammatory profile through the downregulation of the OxPhos
pathway (53). This metabolic reprogramming exacerbates the
inflammatory response and worsens disease progression. NADPH
oxidases (NOXs), particularly NOX2, are critical mediators in this
process (54). These enzymes, located in cellular membranes,
transport electrons to produce cytosolic ROS. While mitochondrial
ROS are often implicated in oxidative stress, NOX-generated ROS are
essential for modulating immune cell activities, including those of T
cells. NOX2, the predominant isoform in T cells, has a dual role in
regulating both effector T cells and Treg (55, 56).

Studies in mice have shown that global NOX2 deficiency leads
to an increase in the number of tissue-resident Treg in the heart
under normal conditions. Furthermore, NOX2 deficiency
suppresses the infiltration of effector T cells, such as Th17 cells, in
response to angiotensin II (Ang II), a key mediator of hypertension,
resulting in reduced Ang II-induced hypertension and associated
cardiac remodeling (57). These findings highlight the intricate role
of NOX2 in balancing immune responses in hypertension. On one
hand, NOX2 is necessary for the proper functioning of effector T
cells, which contribute to inflammatory processes in hypertensive
states. On the other hand, NOX2-derived ROS can impair Treg
suppressive functions, undermining their protective role in
mitigating inflammation and tissue damage.

Insufficient recruitment or downregulation of Treg can lead to
worsened ventricular remodeling due to unchecked pro-
inflammatory responses. Treg mediate immune-inflammatory
regulation through mechanisms such as the release of inhibitory
cytokines, IL-2 consumption, ATP/ADP depletion, and receptor-
ligand interactions. In heart failure, ATP/ADP depletion, often
linked to iron deficiency, induces cardiac oxidative stress,
impairing the activity of antigen-presenting cells and CD8+
effector T cells (58). Promisingly, the systemic administration of
exogenous Treg following myocardial infarction (MI) has been
shown to enhance cardiac function in mice by reducing
cardiomyocyte death and fibrosis (59). Exogenous Treg achieve
this by decreasing pro-inflammatory Ly6ChiCCR2+ monocytes/
macrophages and promoting a shift in macrophages toward a pro-
repair phenotype.

Both adoptive Treg transfer and the expansion of endogenous Treg effectively inhibit the progression of various cardiovascular diseases, highlighting their therapeutic potential. While Treg are generally considered beneficial immune cells in transplantation and tissue repair, their role is context-dependent. Transplantation of NOX-2-deficient Treg has proved to enhance their suppressive ability and migration to heart allografts in mice (60). Amphiregulin (Areg), a Treg-derived epidermal growth factor (EGF), is critical for injury resolution (61). However, a recent study reveals that Areg also contributes to chronic rejection after organ transplantation, promoting graft vascular remodeling and fibrosis, processes exacerbated by Treg activity, oxidative stress and iron dysregulation (62).

Understanding the dual roles of Treg, particularly in
inflammatory and reparative settings, is essential for developing
cell therapies.

Aging

Immunosenescence, the gradual decline in immune function with age, significantly affects Treg, leaving elderly individuals more vulnerable to infections due to suboptimal immune responses to pathogens (63). A hallmark of aging in Treg is the accumulation of reactive oxygen species, which impairs their suppressive capacity and contributes to immune dysregulation. One key molecular mechanism underlying this dysfunction involves the decline in DDB1- and CUL4-associated factor 1 (DCAF1), a crucial factor that diminishes with aging in various tissues. DCAF1 plays an essential role in maintaining Treg functionality by regulating intracellular detoxification processes. Specifically, DCAF1 interacts with glutathione-S-transferase P (GSTP1) to catalyze reactions that buffer ROS, thereby protecting Treg from oxidative damage. The disruption of the DCAF1/GSTP1/ROS axis during aging exacerbates Treg senescence, leading to impaired immune regulation, heightened inflammation, and the progression of immunological aging (64).

Inhibiting ROS accumulation represents a promising strategy to restore Treg function in the elderly. Emerging evidence suggests that iron metabolism also plays a significant role in Treg dysfunction within age. Iron promotes ROS formation through Fenton reactions, and excessive iron accumulation can exacerbate oxidative stress and lipid peroxidation in Treg. This mechanism of ferroptosis could be targeted to prevent age-related disease. In

tumor cell model, GSTP1-related ferroptosis has been described
with possibly similar regulatory mechanisms as for GPX4 on the
ferroptosis pathway (65).

This highlights the interplay between iron homeostasis, cell senescence and immune aging. It suggests that strategies targeting iron metabolism, such as iron chelation or dietary modifications could help mitigate Treg dysfunction by reducing ROS levels. By addressing both ROS accumulation and iron dysregulation, therapeutic interventions could enhance Treg function, reduce age-associated inflammation, and improve immune resilience in the elderly. These approaches may offer new avenues for mitigating the effects of immunosenescence and promoting healthier aging.

Conclusion

The intricate interplay between immunomodulation, Treg, iron metabolism, and energy dynamics constitutes a sophisticated regulatory network that influences hypertension, cardiovascular disease, aging and chronic rejection. Understanding these connections provides valuable insights into novel therapeutic strategies for autoimmune diseases and chronic inflammatory conditions. Future research should focus on elucidating the precise molecular mechanisms involved and translating these findings into clinical applications to optimize therapeutic outcomes.

Author contributions

FS: Writing – original draft, Writing – review & editing. TF:
Writing – review & editing. ZK: Writing – review & editing. MA:
Writing – original draft, Writing – review & editing.

Funding

The author(s) declare that no financial support was received for
the research and/or publication of this article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Generative AI statement

The author(s) declare that no Generative AI was used in the
creation of this manuscript.
## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

## References

1. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. *Nat Genet.* (2001) 27:20–1. doi: 10.1038/83713

2. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. *Nat Genet.* (2001) 27:68–73. doi: 10.1038/83784

3. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. *Nat Immunol.* (2003) 4:330–6. doi: 10.1038/ni904

4. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. *Immunity.* (2005) 22:329–41. doi: 10.1016/j.immuni.2005.01.016

5. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. *Science.* (2003) 299:1057–61. doi: 10.1126/science.1079490

6. Khattri R, Cox T, Yasayko S-A, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. *Nat Immunol.* (2003) 4:337–42. doi: 10.1038/ni909

7. van der Veeken J, Campbell C, Pritykin Y, Schizas M, Verter J, Hu W, et al. Genetic tracing reveals transcription factor Foxp3-dependent and Foxp3-independent functionality of peripherally induced Treg cells. *Immunity.* (2022) 55:1173–1184.e7. doi: 10.1016/j.immuni.2022.05.010

8. Sumida TS, Cheru NT, Hafler DA. The regulation and differentiation of regulatory T cells and their dysfunction in autoimmune diseases. *Nat Rev Immunol.* (2024) 24:503–17. doi: 10.1038/s41577-024-00994-x

9. Hsieh C-S, Lee H-M, Lio C-WJ. Selection of regulatory T cells in the thymus. *Nat Rev Immunol.* (2012) 12:157–67. doi: 10.1038/nri3155

10. Kieback E, Hilgenberg E, Stervbo U, Lampropoulou V, Shen P, Bunse M, et al. Thymus-derived regulatory T cells are positively selected on natural self-antigen through cognate interactions of high functional avidity. *Immunity.* (2016) 44:1114–26. doi: 10.1016/j.immuni.2016.04.018

11. Kanamori M, Nakatsukasa H, Okada M, Lu Q, Yoshimura A. Induced regulatory T cells: their development, stability, and applications. *Trends Immunol.* (2016) 37:803–11. doi: 10.1016/j.it.2016.08.012

12. Shevach EM, Thornton AM. tTregs, pTregs, and iTregs: similarities and differences. *Immunol Rev.* (2014) 259:88–102. doi: 10.1111/imr.12160

13. Junius S, Mavrogiannis AV, Lemaitre P, Gerbaux M, Staels F, Malviya V, et al. Unstable regulatory T cells, enriched for naïve and Nrp1neg cells, are purged after fate challenge. *Sci Immunol.* (2021) 6:eabe4723. doi: 10.1126/sciimmunol.abe4723

14. Zheng Y, Josefowicz S, Chaudhry A, Peng XP, Forbush K, Rudensky AY. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. *Nature.* (2010) 463:808–12. doi: 10.1038/nature08750

15. Yue X, Trifari S, Äijö T, Tsagaratou A, Pastor WA, Zepeda-Martinez JA, et al. Control of Foxp3 stability through modulation of TET activity. *J Exp Med.* (2016) 213:377–97. doi: 10.1084/jem.20151438

16. Wang L, Ozark PA, Smith ER, Zhao Z, Marshall SA, Rendleman EJ, et al. TET2 coactivates gene expression through demethylation of enhancers. *Sci Adv.* (2018) 4: eaua6986. doi: 10.1126/sciadv.aua6986

17. Salminen A, Kauppinen A, Kaarniranta K. 2-Oxoglutarate-dependent dioxygenases are sensors of energy metabolism, oxygen availability, and iron homeostasis: potential role in the regulation of aging process. *Cell Mol Life Sci.* (2015) 72:3897–914. doi: 10.1007/s00018-015-1978-z

18. Brasse-Lagnel C, Karim Z, Letteron P, Bekri S, Bado A, Beaumont C. Intestinal DMT1 cotransporter is down-regulated by hepcidin via proteasome internalization and degradation. *Gastroenterology.* (2011) 140:1261–1271.e1. doi: 10.1053/j.gastro.2010.12.037

19. Daher R, Manceau H, Karim Z. Iron metabolism and the role of the iron-regulating hormone hepcidin in health and disease. *Presse Med.* (2017) 46:e272–8. doi: 10.1016/j.lpm.2017.10.006

20. Mastrogiannaki M, Matak P, Keith B, Simon MC, Vaulont S, Peyssonnaux C. HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice. *J Clin Invest.* (2009) 119:1159–66. doi: 10.1172/JCI38499

21. Batista A, Millán J, Mittelbrunn M, Sánchez-Madrid F, Alonso MA. Recruitment of transferrin receptor to immunological synapse in response to

TCR engagement. *J Immunol.* (2004) 172:6709–14. doi: 10.4049/jimmunol.172.11.6709

22. Vanoaica L, Richman L, Jaworski M, Darshan D, Luther SA, Kühn LC. Conditional deletion of ferritin H in mice reduces B and T lymphocyte populations. *PloS One.* (2014) 9:e89270. doi: 10.1371/journal.pone.0089270

23. Voss K, Sewell AE, Krystofiak ES, Gibson-Corley KN, Young AC, Basham JH, et al. Elevated transferrin receptor impairs T cell metabolism and function in systemic lupus erythematosus. *Sci Immunol.* (2023) 8:eabq0178. doi: 10.1126/sciimmunol.abq0178

24. Wu Q, Carlos AR, Braza F, Bergman M-L, Kitoko JZ, Bastos-Amador P, et al. Ferritin heavy chain supports stability and function of the regulatory T cell lineage. *EMBO J.* (2024) 43:1445–83. doi: 10.1038/s44318-024-00064-x

25. Klemm P, Rajendiran A, Fragoulis A, Wruck C, Schippers A, Wagner N, et al. Nrf2 expression driven by Foxp3 specific deletion of Keap1 results in loss of immune tolerance in mice. *Eur J Immunol.* (2020) 50:515–24. doi: 10.1002/eji.201948285

26. Pastor WA, Aravind L, Rao A. TETonic shift: biological roles of TET proteins in DNA demethylation and transcription. *Nat Rev Mol Cell Biol.* (2013) 14:341–56. doi: 10.1038/nrm3589

27. Zhu L, Li G, Liang Z, Qi T, Deng K, Yu J, et al. Microbiota-assisted iron uptake promotes immune tolerance in the intestine. *Nat Commun.* (2023) 14:2790. doi: 10.1038/s41467-023-38444-2

28. Xu M, Pokrovskii M, Ding Y, Yi R, Au C, Harrison OJ, et al. c-MAF-dependent regulatory T cells mediate immunological tolerance to a gut pathobiont. *Nature.* (2018) 554:373–7. doi: 10.1038/nature25500

29. Gu Y, Bartolomé-Casado R, Xu C, Bertocchi A, Janney A, Heuberger C, et al. Immune microniches shape intestinal Treg function. *Nature.* (2024) 628:854–62. doi: 10.1038/s41586-024-07251-0

30. Pacella I, Grimaldos AP, Rossi A, Tucci G, Zagaglioni M, Potenza E, et al. Iron capture through CD71 drives perinatal and tumor-associated Treg expansion. *JCI Insight.* (2024) 9(15):e167967. doi: 10.1172/jci.insight.167967

31. Liu Z, Zhang Z, Zhang Y, Zhou W, Zhang X, Peng C, et al. Spatial transcriptomics reveals that metabolic characteristics define the tumor immunosuppression microenvironment via iCAF transformation in oral squamous cell carcinoma. *Int J Oral Sci.* (2024) 16:1–12. doi: 10.1038/s41368-023-00267-8

32. Zeng H, Yang K, Cloer C, Neale G, Vogel P, Chi H. mTORC1 couples immune signals and metabolic programming to establish Treg-cell function. *Nature.* (2013) 499:485–90. doi: 10.1038/nature12297

33. Härm J, Fan Y-T, Brenner D. Navigating the metabolic landscape of regulatory T cells: from autoimmune diseases to tumor microenvironments. *Curr Opin Immunol.* (2025) 92:102511. doi: 10.1016/j.coi.2024.102511

34. Xu C, Sun S, Johnson T, Qi R, Zhang S, Zhang J, et al. The glutathione peroxidase Gpx4 prevents lipid peroxidation and ferroptosis to sustain Treg cell activation and suppression of antitumor immunity. *Cell Rep.* (2021) 35:109235. doi: 10.1016/j.celrep.2021.109235

35. Weinberg SE, Singer BD, Steinert EM, Martinez CA, Mehta MM, Martinez-Reyes I, et al. Mitochondrial complex III is essential for suppressive function of regulatory T cells. *Nature.* (2019) 565:495–9. doi: 10.1038/s41586-018-0846-z

36. Angelin A, Gil-de-Gómez L, Dahiya S, Jiao J, Guo L, Levine MH, et al. Foxp3 reprograms T cell metabolism to function in low-glucose, high-lactate environments. *Cell Metab.* (2017) 25:1282–1293.e7. doi: 10.1016/j.cmet.2016.12.018

37. Newton R, Priyadharshini B, Turka LA. Immunometabolism of regulatory T cells. *Nat Immunol.* (2016) 17:618–25. doi: 10.1038/ni.3466

38. Alissafi T, Kalafati L, Lazari M, Filia A, Kloukina I, Manifava M, et al. Mitochondrial oxidative damage underlies regulatory T cell defects in autoimmunity. *Cell Metab.* (2020) 32:591–604.e7. doi: 10.1016/j.cmet.2020.07.001

39. Li Y, Goronzy JJ, Weyand CM. DNA damage, metabolism and aging in pro-inflammatory T cells rheumatoid arthritis as a model system. *Exp Gerontol.* (2018) 105:118–27. doi: 10.1016/j.exger.2017.10.027

40. Pucino V, Certo M, Bulusu V, Cucchi D, Goldmann K, Pontarini E, et al. Lactate buildup at the site of chronic inflammation promotes disease by inducing CD4+ T cell metabolic rewiring. *Cell Metab.* (2019) 30:1055–1074.e8. doi: 10.1016/j.cmet.2019.10.004

41. Souto-Carneiro MM, Klika KD, Abreu MT, Meyer AP, Saffrich R, Sandhoff R, et al. Effect of increased lactate dehydrogenase A activity and aerobic glycolysis on the
proinflammatory profile of autoimmune CD8+ T cells in rheumatoid arthritis. *Arthritis Rheumatol.* (2020) 72:2050–64. doi: 10.1002/art.41420

42. Weyand CM, Fujii H, Shao L, Goronzy JJ. Rejuvenating the immune system in rheumatoid arthritis. *Nat Rev Rheumatol.* (2009) 5:583–8. doi: 10.1038/nrrheum.2009.180

43. Wu B, Zhao TV, Jin K, Hu Z, Abdel MP, Warrington KJ, et al. Mitochondrial aspartate regulates TNF biogenesis and autoimmune tissue inflammation. *Nat Immunol.* (2021) 22:1551–62. doi: 10.1038/s41590-021-01065-2

44. Kurniawan H, Soriano-Baguet L, Brenner D. Regulatory T cell metabolism at the intersection between autoimmune diseases and cancer. *Eur J Immunol.* (2020) 50:1626–42. doi: 10.1002/eji.201948470

45. Chen J, Lu W-Y, Zhao M-F, Cao X-L, Jiang Y-Y, Jin X, et al. Reactive oxygen species mediated T lymphocyte abnormalities in an iron-overloaded mouse model and iron-overloaded patients with myelodysplastic syndromes. *Ann Hematol.* (2017) 96:1085–95. doi: 10.1007/s00277-017-2985-y

46. Matsui K, Ezoe S, Yokota T, Ishibashi T, Oritani K, Kanakura Y. Iron overload effects on immune system through the cytokine secretion by macrophage. *Blood.* (2013) 122:1047. doi: 10.1182/blood.V122.21.1047.1047

47. ScIndia Y, Wlazlo E, Ghias E, Cechova S, Loi V, Leeds J, et al. Modulation of iron homeostasis with hepcidin ameliorates spontaneous murine lupus nephritis. *Kidney Int.* (2020) 98:100–15. doi: 10.1016/j.kint.2020.01.025

48. Gao X, Song Y, Lu S, Hu L, Zheng M, Jia S, et al. Insufficient iron improves pristane-induced lupus by promoting treg cell expansion. *Front Immunol.* (2022) 13:799331. doi: 10.3389/fimmu.2022.799331

49. Hisada R, Kono M. Potential therapies targeting metabolic pathways in systemic lupus erythematosus. *Clin Immunol.* (2024) 263:110224. doi: 10.1016/j.clim.2024.110224

50. GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet.* (2018) 392:1923–94. doi: 10.1016/S0140-6736(18)32225-6

51. Griendling KK, Camargo LL, Rios FJ, Alves-Lopes R, Montezano AC, Touyz RM. Oxidative stress and hypertension. *Circ Res.* (2021) 128:993–1020. doi: 10.1161/CIRCRESAHA.121.318063

52. Te Riet L, van Esch JHM, Roks AJM, van den Meiracker AH, Danser AHJ. Hypertension: renin-angiotensin-aldosterone system alterations. *Circ Res.* (2015) 116:960–75. doi: 10.1161/CIRCRESAHA.116.303587

53. Cörte-Real BF, Hamad I, Arroyo Hornero R, Geisberger S, Roels J, Van Zeebroeck L, et al. Sodium perturbs mitochondrial respiration and induces

dysfunctional Tregs. *Cell Metab.* (2023) 35:299–315.e8. doi: 10.1016/j.cmet.2023.01.009

54. Lassègue B, San Martin A, Griendling KK. Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. *Circ Res.* (2012) 110:1364–90. doi: 10.1161/CIRCRESAHA.111.243972

55. Augsburger F, Filippova A, Rasti D, Seredenina T, Lam M, Maghzal G, et al. Pharmacological characterization of the seven human NOX isoforms and their inhibitors. *Redox Biol.* (2019) 26:101272. doi: 10.1016/j.redox.2019.101272

56. Kwon J, Shatynski KE, Chen H, Morand S, de Deken X, Miot F, et al. The nonphagocytic NADPH oxidase duox1 mediates a positive feedback loop during T cell receptor signaling. *Sci Signal.* (2010) 3:ra59. doi: 10.1126/scisignal.2000976

57. Emmerson A, Trevelin SC, Mongue-Din H, Becker PD, Ortiz C, Smyth LA, et al. Nox2 in regulatory T cells promotes angiotensin II-induced cardiovascular remodeling. *J Clin Invest.* (2018) 128:3088–101. doi: 10.1172/JCI97490

58. Bansal SS, Ismahil MA, Goel M, Zhou G, Rokosh G, Hamid T, et al. Dysfunctional and proinflammatory regulatory T-lymphocytes are essential for adverse cardiac remodeling in ischemic cardiomyopathy. *Circulation.* (2019) 139:206–21. doi: 10.1161/CIRCULATIONAHA.118.036065

59. Alshoubaki YK, Nayer B, Lu Y-Z, Salimova E, Lau SN, Tan JL, et al. Tregs delivered post-myocardial infarction adopt an injury-specific phenotype promoting cardiac repair via macrophages in mice. *Nat Commun.* (2024) 15:6480. doi: 10.1038/s41467-024-50806-y

60. Trevelin SC, Zampetaki A, Sawyer G, Ivetic A, Brewer AC, Smyth LA, et al. Nox2-deficient Tregs improve heart transplant outcomes via their increased graft recruitment and enhanced potency. *JCI Insight.* (2021) 6:e149301. doi: 10.1172/jci.insight.149301

61. Dwyer GK, D'Cruz LM, Turnquist HR. Emerging functions of IL-33 in homeostasis and immunity. *Annu Rev Immunol.* (2022) 40:15–43. doi: 10.1146/annurev-immunol-101320-124243

62. Warunek JJP, Fan L, Zhang X, Wang S, Sanders SM, Li T, et al. Dysregulated Treg repair responses lead to chronic rejection after heart transplantation. *J Clin Invest.* (2024) 134(23):e173593. doi: 10.1172/JCI173593

63. Martinez F, Novarino J, Mejia JE, Fazilleau N, Aloulou M. Ageing of T-dependent B cell responses. *Immunol Lett.* (2021) 233:97–103. doi: 10.1016/j.imlet.2021.03.012

64. Guo Z, Wang G, Wu B, Chou W-C, Cheng L, Zhou C, et al. DCAF1 regulates Treg senescence via the ROS axis during immunological aging. *J Clin Invest.* (2020) 130:5893–908. doi: 10.1172/JCI136466

65. Tan X, Huang X, Niu B, Guo X, Lei X, Qu B. Targeting GSTP1-dependent ferroptosis in lung cancer radiotherapy: Existing evidence and future directions. *Front Mol Biosci.* (2022) 9:1102158. doi: 10.3389/fmolb.2022.1102158